These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28066999)

  • 61. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pretransplantation assessment of the risk of lymphoproliferative disorder.
    Walker RC; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; McGregor CG; Paya CV
    Clin Infect Dis; 1995 May; 20(5):1346-53. PubMed ID: 7620022
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pattern analysis of Epstein-Barr virus viremia and its significance in the evaluation of organ transplant patients suspected of having posttransplant lymphoproliferative disorders.
    Cho YU; Chi HS; Jang S; Park SH; Park CJ
    Am J Clin Pathol; 2014 Feb; 141(2):268-74. PubMed ID: 24436276
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study.
    Allen UD; Farkas G; Hébert D; Weitzman S; Stephens D; Petric M; Tellier R; Ngan B; Fecteau A; West L; Wasfy S
    Pediatr Transplant; 2005 Aug; 9(4):450-5. PubMed ID: 16048596
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Viral infections in solid organ transplant recipients: novel updates and a review of the classics.
    Haidar G; Singh N
    Curr Opin Infect Dis; 2017 Dec; 30(6):579-588. PubMed ID: 28984642
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM; Adams W; Grim SA; Clark NM; Edwards L; Layden JE
    J Cyst Fibros; 2017 Nov; 16(6):727-734. PubMed ID: 28456611
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Identification of Optimal Donor-Recipient Combinations Among Human Immunodeficiency Virus (HIV)-Positive Kidney Transplant Recipients.
    Locke JE; Shelton BA; Reed RD; MacLennan PA; Mehta S; Sawinski D; Segev DL
    Am J Transplant; 2016 Aug; 16(8):2377-83. PubMed ID: 27140837
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients.
    Hopwood PA; Brooks L; Parratt R; Hunt BJ; Bokhari M; Thomas JA; Yacoub M; Crawford DH
    Transplantation; 2002 Jul; 74(2):194-202. PubMed ID: 12151731
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
    Razonable RR; Humar A
    Clin Transplant; 2019 Sep; 33(9):e13512. PubMed ID: 30817026
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients.
    Marques HH; Shikanai-Yasuda MA; dAzevedo LS; Caiaffa-Filho HH; Pierrotti LC; Aquino MZ; Lopes MH; Maluf NZ; Campos SV; Costa SF
    Rev Soc Bras Med Trop; 2014; 47(5):543-6. PubMed ID: 25467252
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Limited Utility of Serology and Heterophile Test in the Early Diagnosis of Epstein-Barr Virus Mononucleosis in a Child after Renal Transplantation.
    Byrne A; Bush R; Johns F; Upadhyay K
    Medicines (Basel); 2020 Apr; 7(4):. PubMed ID: 32331303
    [No Abstract]   [Full Text] [Related]  

  • 77. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
    Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.
    Maloney EM; Busque VA; Hui ST; Toh J; Fernandez-Vina M; Krams SM; Esquivel CO; Martinez OM
    JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32213705
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Aggressive Epstein-Barr virus-negative B-cell post-transplant lymphoproliferative disorder in a hepatitis C-negative liver transplant recipient who received a hepatitis C-positive graft: Implications for D+/R- hepatitis C virus seroconversion.
    Kutzler HL; Collins K; Maneckshana B; Rochon C; Einstein M; Mnayer L; Rezuke WN; Sheiner P; Serrano OK
    Transpl Infect Dis; 2019 Oct; 21(5):e13144. PubMed ID: 31291501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.